Alyson Haslam

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 47

Top Topics

Systematic Review

Top Venues

Epidemiology and infection

Cancer medicine

British journal of haematology

International journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Tracy Beth Høeg, Alyson Haslam, Vinay Prasad
The importance of falsification endpoints in observational studies of vaccination to prevent severe disease: A critique of a harm-benefit analysis of BNT162b2 vaccination of 5- to 11-year-olds. Epidemiology and infection 152 (2024)
Sarah L Miller, Alyson Haslam, Vinay Prasad
Financial conflicts of interest among presenters, panellists and moderators at haematology and oncology FDA workshops. European journal of clinical investigation 54 (6) (2024)
Timothée Olivier, Alyson Haslam, Patricia Burke, Isabelle Boutron, Florian Naudet, John P A Ioannidis, Vinay Prasad
A novel framework to assess haematology and oncology registration trials: The THEOREMM project. European journal of clinical investigation (2024)
Tracy Beth Høeg, Alyson Haslam, Vinay Prasad
The importance of falsification endpoints in observational studies of vaccination to prevent severe disease: A critique of a harm-benefit analysis of BNT162b2 vaccination of 5- to 11-year-olds. Epidemiology and infection 152 (2024)
Adam Khan, Hassan Khan, Griffin K Hughes, Chase Ladd, Ryan McIntire, Brooke Gardner, Andriana M Peña, Abigail Schoutko, Jordan Tuia, Kirstien Minley, Alyson Haslam, Vinay Prasad, Matt Vassar
Assessing patient risk, benefit, and outcomes in drug development: A decade of ramucirumab clinical trials. Cancer medicine 13 (9) (2024)
Adam Khan, Hassan Khan, Griffin K Hughes, Chase Ladd, Ryan McIntire, Brooke Gardner, Andriana M Peña, Abigail Schoutko, Jordan Tuia, Kirstien Minley, Alyson Haslam, Vinay Prasad, Matt Vassar
Assessing patient risk, benefit, and outcomes in drug development: A decade of ramucirumab clinical trials. Cancer medicine 13 (9) (2024)
Christopher O Eden, Alyson Haslam, Vinay Prasad
Cancer Therapy, Gonadal Function, and Fertility Preservation: Narrative Review. JCO oncology practice (2024)
Josh Elbaz, Alyson Haslam, Vinay Prasad
An empirical analysis of overall survival in drug approvals by the US FDA (2006-2023). Cancer medicine 13 (8) (2024)
Tracy Beth Høeg, Alyson Haslam, Vinay Prasad
The importance of falsification endpoints in observational studies of vaccination to prevent severe disease: A critique of a harm-benefit analysis of BNT162b2 vaccination of 5- to 11-year-olds. Epidemiology and infection 152 (2024)
Tracy Beth Høeg, Alyson Haslam, Vinay Prasad
The importance of falsification endpoints in observational studies of vaccination to prevent severe disease: A critique of a harm-benefit analysis of BNT162b2 vaccination of 5- to 11-year-olds. Epidemiology and infection 152 (2024)
Tracy Beth Høeg, Alyson Haslam, Vinay Prasad
The importance of falsification endpoints in observational studies of vaccination to prevent severe disease: A critique of a harm-benefit analysis of BNT162b2 vaccination of 5- to 11-year-olds. Epidemiology and infection 152 (2024)
David J Benjamin, Alyson Haslam, Vinay Prasad
Cardiovascular/anti-inflammatory drugs repurposed for treating or preventing cancer: A systematic review and meta-analysis of randomized trials. Cancer medicine 13 (5) (2024)
Josh Elbaz, Alyson Haslam, Vinay Prasad
An empirical analysis of overall survival in drug approvals by the US FDA (2006-2023). Cancer medicine 13 (8) (2024)
Sarah L Miller, Alyson Haslam, Vinay Prasad
Financial conflicts of interest among presenters, panellists and moderators at haematology and oncology FDA workshops. European journal of clinical investigation (2024)
Tracy Beth Høeg, Alyson Haslam, Vinay Prasad
The importance of falsification endpoints in observational studies of vaccination to prevent severe disease: A critique of a harm-benefit analysis of BNT162b2 vaccination of 5- to 11-year-olds. Epidemiology and infection 152 (2024)
Tracy Beth Høeg, Alyson Haslam, Vinay Prasad
The importance of falsification endpoints in observational studies of vaccination to prevent severe disease: A critique of a harm-benefit analysis of BNT162b2 vaccination of 5- to 11-year-olds. Epidemiology and infection 152 (2024)
Tracy Beth Høeg, Alyson Haslam, Vinay Prasad
The importance of falsification endpoints in observational studies of vaccination to prevent severe disease: A critique of a harm-benefit analysis of BNT162b2 vaccination of 5- to 11-year-olds. Epidemiology and infection 152 (2024)
Tracy Beth Høeg, Alyson Haslam, Vinay Prasad
The importance of falsification endpoints in observational studies of vaccination to prevent severe disease: A critique of a harm-benefit analysis of BNT162b2 vaccination of 5- to 11-year-olds. Epidemiology and infection 152 (2024)
Adam Khan, Hassan Khan, Griffin K Hughes, Chase Ladd, Ryan McIntire, Brooke Gardner, Andriana M Peña, Abigail Schoutko, Jordan Tuia, Kirstien Minley, Alyson Haslam, Vinay Prasad, Matt Vassar
Assessing patient risk, benefit, and outcomes in drug development: A decade of ramucirumab clinical trials. Cancer medicine 13 (9) (2024)
David J Benjamin, Alyson Haslam, Vinay Prasad
Cardiovascular/anti-inflammatory drugs repurposed for treating or preventing cancer: A systematic review and meta-analysis of randomized trials. Cancer medicine 13 (5) (2024)
Griffin K Hughes, Nicholas B Sajjadi, Brooke Gardner, Joshua K Ramoin, Jordan Tuia, Alyson Haslam, Vinay Prasad, Matt Vassar
Assessing patient burden and benefit: A decade of cabozantinib clinical trials. International journal of cancer 154 (8) (2023)
Alyson Haslam, Tracy Beth Høeg, Vinay Prasad
Estimation of eligibility for and response to CAR-T therapy in the United States. Blood advances (2023)
Griffin K Hughes, Nicholas B Sajjadi, Brooke Gardner, Joshua K Ramoin, Jordan Tuia, Alyson Haslam, Vinay Prasad, Matt Vassar
Assessing patient burden and benefit: A decade of cabozantinib clinical trials. International journal of cancer 154 (8) (2023)
Jordan E Tuia, Alyson Haslam, Vinay Prasad
Profile of the Oncology Physician Workforce and the Characteristics of Attrition. JCO oncology practice (2023)
Griffin K Hughes, Nicholas B Sajjadi, Brooke Gardner, Joshua K Ramoin, Jordan Tuia, Alyson Haslam, Vinay Prasad, Matt Vassar
Assessing patient burden and benefit: A decade of cabozantinib clinical trials. International journal of cancer (2023)
Elissa Brown, Alyson Haslam, Vinay Prasad
Flu advice in the U.S. news media changed during the COVID-19 pandemic but not the evidence. European journal of epidemiology (2023)
Alyson Haslam, Timothée Olivier, Vinay Prasad
The definition of long COVID used in interventional studies. European journal of clinical investigation (2023)
Griffin K Hughes, Nicholas B Sajjadi, Brooke Gardner, Joshua K Ramoin, Jordan Tuia, Alyson Haslam, Vinay Prasad, Matt Vassar
Assessing patient burden and benefit: A decade of cabozantinib clinical trials. International journal of cancer 154 (8) (2023)
Tommy Etekal, Kelly Koehn, Douglas W Sborov, Brian McClune, Vinay Prasad, Alyson Haslam, Katherine Berger, Christopher Booth, Samer Al Hadidi, Al-Ola Abdallah, Aaron Goodman, Ghulam Rehman Mohyuddin
Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis. British journal of haematology (2022)
Alyson Haslam, Charlotte Love, Tori Taniguchi, Mary B Williams, Marianna S Wetherill, Susan Sisson, Ashley E Weedn, Tvli Jacob, Valarie Blue Bird Jernigan
Development and Implementation of a Hybrid Online and In-Person Food Sovereignty and Nutrition Education Curriculum for Native American Parents: The FRESH Study. Health education & behavior : the official publication of the Society for Public Health Education (2022)
Alyson Haslam, Vinay Prasad
Characteristics of Facebook's third-party medical fact checkers. Digital health 8 (2022)
Tommy Etekal, Kelly Koehn, Douglas W Sborov, Brian McClune, Vinay Prasad, Alyson Haslam, Katherine Berger, Christopher Booth, Samer Al Hadidi, Al-Ola Abdallah, Aaron Goodman, Ghulam Rehman Mohyuddin
Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis. British journal of haematology 200 (5) (2022)
Kristina Jenei, Alyson Haslam, Timothée Olivier, Milos Miljkovíc, Vinay Prasad
What drives cancer clinical trial accrual? An empirical analysis of studies leading to FDA authorisation (2015-2020). BMJ open 12 (10) (2022)
Alyson Haslam, Jennifer Gill, Tori Taniguchi, Charlotte Love, Valarie Bluebird Jernigan
The effect of food prescription programs on chronic disease management in primarily low-income populations: A systematic review and meta-analysis. Nutrition and health 28 (3) (2022)
Alyson Haslam, Timothée Olivier, Kerrington Powell, Jordan Tuia, Vinay Prasad
Eventual success rate and predictors of success for oncology drugs tested in phase I trials. International journal of cancer 152 (2) (2022)
Tommy Etekal, Kelly Koehn, Douglas W Sborov, Brian McClune, Vinay Prasad, Alyson Haslam, Katherine Berger, Christopher Booth, Samer Al Hadidi, Al-Ola Abdallah, Aaron Goodman, Ghulam Rehman Mohyuddin
Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis. British journal of haematology 200 (5) (2022)
Tommy Etekal, Kelly Koehn, Douglas W Sborov, Brian McClune, Vinay Prasad, Alyson Haslam, Katherine Berger, Christopher Booth, Samer Al Hadidi, Al-Ola Abdallah, Aaron Goodman, Ghulam Rehman Mohyuddin
Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis. British journal of haematology 200 (5) (2022)
Tommy Etekal, Kelly Koehn, Douglas W Sborov, Brian McClune, Vinay Prasad, Alyson Haslam, Katherine Berger, Christopher Booth, Samer Al Hadidi, Al-Ola Abdallah, Aaron Goodman, Ghulam Rehman Mohyuddin
Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis. British journal of haematology (2022)
Tommy Etekal, Kelly Koehn, Douglas W Sborov, Brian McClune, Vinay Prasad, Alyson Haslam, Katherine Berger, Christopher Booth, Samer Al Hadidi, Al-Ola Abdallah, Aaron Goodman, Ghulam Rehman Mohyuddin
Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis. British journal of haematology 200 (5) (2022)
Tommy Etekal, Kelly Koehn, Douglas W Sborov, Brian McClune, Vinay Prasad, Alyson Haslam, Katherine Berger, Christopher Booth, Samer Al Hadidi, Al-Ola Abdallah, Aaron Goodman, Ghulam Rehman Mohyuddin
Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis. British journal of haematology 200 (5) (2022)
Alyson Haslam, Kerrington Powell, Vinay Prasad
How Often do Medical Specialties Question the Practices that They Perform? An Empirical, Cross-Sectional Analysis of the Published Literature. Inquiry : a journal of medical care organization, provision and financing 59 (2022)
Alyson Haslam, Jennifer Gill, Vinay Prasad
The frequency of assessment of progression in randomized oncology clinical trials. Cancer reports (Hoboken, N.J.) (2021)
Alyson Haslam, Jennifer Gill, Vinay Prasad
The response rate of alternative treatments for drugs approved on the basis of response rate. International journal of cancer 148 (3) (2020)
Edward B Maldonado, Scott Parsons, Emerson Y Chen, Alyson Haslam, Vinay Prasad
Estimation of US patients with cancer who may respond to cytotoxic chemotherapy. Future science OA 6 (8) (2020)
Diana Herrera-Perez, Alyson Haslam, Tyler Crain, Jennifer Gill, Catherine Livingston, Victoria Kaestner, Michael Hayes, Dan Morgan, Adam S Cifu, Vinay Prasad
A comprehensive review of randomized clinical trials in three medical journals reveals 396 medical reversals. eLife 8 (2019)
Alyson Haslam, Vinay Prasad, Catherine Livingston
Medical reversals in low- and middle-income countries. The International journal of health planning and management 35 (2) (2019)
Alyson Haslam, Sara Wagner Robb, James R Hébert, Hanwen Huang, Mark H Ebell
Association between dietary pattern scores and the prevalence of colorectal adenoma considering population subgroups. Nutrition & dietetics: the journal of the Dietitians Association of Australia 75 (2) (2017)